🔗 Share this article

While America continues making unprecedented revisions to its vaccination recommendations, one figure has surfaced somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 shots throughout the global health crisis and has focused upon possible fatalities following Covid immunization in her short tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Health officials planned to unveil sweeping revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with many the global community with insufficient data for public health gain. The announcement has been delayed until the next year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth individual to head the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the agency – and it points to a renewed priority upon dismantling already-approved immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific pediatric shot schedules in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.

To date statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.

Doubts Over Qualifications

Høeg has no obvious experience in pharmaceutical research, approval processes or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the CDER, remarked Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She lacks background in pharmaceutical oversight.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the science of drug development”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who led the center have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock stated.

“Many people just zeroes in on the new drug program, but the generic drug division authorizes thousands of generic medications. There is also a biosimilars division, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the role, which oversees in excess of 5,000 staff members. “It is a massive management job, if you do it right,” Woodcock said.

Official Statement and Contentious Initiatives

Regarding questions about Høeg’s qualifications and whether this appointment signifies greater collaboration among agency officials on immunizations, a press secretary responded that the “inquiries rely on incorrect assumptions”.

“This background aligns with the responsibilities of her job,” the spokesperson stated, noting the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed one-day medication authorization process that allegedly troubled her preceding directors. “How are these medications being chosen for this fast-track system? Who takes the calls?” Dr. Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer oversight of all drugs, except for shots.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if problematic, track record, some experts observe. She published a study using non-validated volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the new government included altering guidelines for novel immunizations and discontinuing “optional” vaccines, she stated post-election on a podcast. At the FDA, Høeg has according to sources floated the idea of barring teenage boys from getting Covid vaccinations.

“She’s an all-around true believer who commences with her beliefs and reverse-engineers to retrofit the science in a very deceptive, dishonest manner,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg joined other dissenters, {like|